Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of DS-9606a in Advanced Solid Tumors
NCT05394675Phase 1Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2022
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of DS-9606 in solid tumor (advanced stage), metastatic solid tumor and germ cell tumor (GCT), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-Limiting Toxicities and Treatment-emergent Adverse Events. Started May 2022; status: terminated.
02
Drugs
DS-9606
03
Conditions
solid tumor (advanced stage)metastatic solid tumorgerm cell tumor (GCT)
Beyond the preview
Go deeper on NCT05394675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394675.